



Clinical Development in Multiple Sclerosis Diagnosis and Treatment

Guest Editor:

Dr. Majid Ghareghani

Neuroscience Laboratory, CHU
de Québec Research Centre,
Department of Molecular
Medicine, Faculty of Medicine,
Laval University, Québec City, QC
G1V 4G2, Canada

Deadline for manuscript
submissions:
closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,


Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease that continues to challenge clinicians and researchers alike. Recent years have seen a surge in our understanding of the pathogenesis and treatment options for MS, yet there is still much to be uncovered. The application of humoral, clinical, or digital biomarkers to detect early onset or monitor disease progression has become commonplace. A biomarker precisely reflecting the inflammatory and degenerative components of MS would allow for therapies to be exactly adapted, reducing delays in treatment optimization. The call for robust molecular and cellular biomarkers to evaluate MS therapies is more urgent than ever.

This Special Issue focuses on enhancing our understanding and advancing the field of MS through innovative research on biomarkers. We are inviting original research articles and reviews that explore: Pharmacogenomics and Proteomics in MS, Systems Biology in MS, Omics Association Analysis in MS and Clinical Development of MS Biomarkers.

Guest Editor

Dr. Majid Ghareghan





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)